董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cameron Reynolds | 男 | President,Chief Executive Officer and Director | 55 | 69.00万美元 | 未持股 | 2026-01-31 |
| Guy Innes | 男 | Director | 70 | 10.45万美元 | 未持股 | 2026-01-31 |
| Alan Colman | 男 | Director | 78 | 11.70万美元 | 未持股 | 2026-01-31 |
| Timothy Still | 男 | Non-executive Chairman of the Board | 59 | 未披露 | 未持股 | 2026-01-31 |
| Phillip Barnes | 男 | Director | 63 | 未披露 | 未持股 | 2026-01-31 |
| Mickie Henshall | 女 | Director | 53 | 未披露 | 未持股 | 2026-01-31 |
| Kim Nguyen | 女 | Director | 48 | 未披露 | 未持股 | 2026-01-31 |
| Ethel Rubin | 女 | Director | 56 | 未披露 | 未持股 | 2026-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cameron Reynolds | 男 | President,Chief Executive Officer and Director | 55 | 69.00万美元 | 未持股 | 2026-01-31 |
| Rodney Rootsaert | 男 | Corporate Secretary | 55 | 26.27万美元 | 未持股 | 2026-01-31 |
| Jacob Micallef | 男 | Chief Scientific Officer | 70 | 41.94万美元 | 未持股 | 2026-01-31 |
| Gael Forterre | 男 | Chief Commercial Officer | 45 | 未披露 | 未持股 | 2026-01-31 |
| Terig Hughes | 男 | Chief Financial Officer and Treasurer | 55 | 未披露 | 未持股 | 2026-01-31 |
| Gaetan Michel | 男 | Chief Operating Officer | 52 | 未披露 | 未持股 | 2026-01-31 |
| Andrew Retter | 男 | Chief Medical Officer | 48 | 未披露 | 未持股 | 2026-01-31 |
| Nicholas Plummer | 男 | Group General Counsel | 54 | 未披露 | 未持股 | 2026-01-31 |
| Louise Batchelor | 女 | Group Chief Marketing & Communications Officer | 54 | 未披露 | 未持股 | 2026-01-31 |
| Jasmine Kway | 女 | Chief Executive Officer, Singapore Volition | 53 | 未披露 | 未持股 | 2026-01-31 |
董事简历
中英对照 | 中文 | 英文- Cameron Reynolds
-
Cameron Reynolds是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
Cameron Reynolds was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX:OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds'main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC;Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V:CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V:HBY). - Cameron Reynolds是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
- Cameron Reynolds was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX:OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds'main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC;Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V:CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V:HBY).
- Guy Innes
-
Guy Innes担任董事。在换股协议之前，Innes先生担任新加坡Volition的董事，2010年8月18日至2015年12月15日一直担任此职务。Innes先生担任公司的非执行董事，如 2007年至2010年的Carbon Mining Plc，2007年至2010年的Magellan Copper & Gold Plc，2000年至2006年的ProBio公司。作为非执行董事，Innes先生负责公司战略发展，财务控制和风险管理制度的执行情况。Innes先生曾在银行和私募股权有漫长的职业生涯，其中包括1997年至2000年在Quartz Capital Partners Limited担任咨询职务，在那里Innes先生担任公司财务总监，负责管理公司财务部门和领导 Quartz所进行的交易包括首次公开发行、私募和并购；1995年至1997年在伦敦和新加坡Baring Private Equity Partners Limited，在那里他曾参与设立、管理和融资亚洲媒体和私募基金；1984年至1995年在伦敦和巴黎的Baring Brothers & Co. Limited任职，他参与并执行国家和国际并购咨询，首次公开发行和资金筹集。
Guy Innes,served as a Director of Singapore Volition, a position he held from August 18, 2010 to December 15, 2015. Mr. Innes has served as a non-executive Director on the boards of mineral exploration companies such as Carbon Mining PLC and Magellan Copper & Gold PLC, both from 2007 to 2010, and on the board of ProBio Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii, from 2000 to 2006. Mr. Innes had a long career in banking and private equity, including advisory roles with Quartz Capital Partners Limited, or Quartz, a small London based investment bank specializing in new technology companies, from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including initial public offerings, private placements and mergers and acquisitions; Baring Private Equity Partners Limited, a private equity investment firm, in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Baring Brothers & Co. Limited, a London based international investment bank, in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers and acquisitions, as well as initial public offerings and capital raising. Mr. Innes is a chartered accountant and a member of the Institute of Chartered Accountants in England and Wales. Mr. Innes has extensive experience in financing and managing technology companies. Mr. Innes received a B.Sc. in Geography from Bristol University. - Guy Innes担任董事。在换股协议之前，Innes先生担任新加坡Volition的董事，2010年8月18日至2015年12月15日一直担任此职务。Innes先生担任公司的非执行董事，如 2007年至2010年的Carbon Mining Plc，2007年至2010年的Magellan Copper & Gold Plc，2000年至2006年的ProBio公司。作为非执行董事，Innes先生负责公司战略发展，财务控制和风险管理制度的执行情况。Innes先生曾在银行和私募股权有漫长的职业生涯，其中包括1997年至2000年在Quartz Capital Partners Limited担任咨询职务，在那里Innes先生担任公司财务总监，负责管理公司财务部门和领导 Quartz所进行的交易包括首次公开发行、私募和并购；1995年至1997年在伦敦和新加坡Baring Private Equity Partners Limited，在那里他曾参与设立、管理和融资亚洲媒体和私募基金；1984年至1995年在伦敦和巴黎的Baring Brothers & Co. Limited任职，他参与并执行国家和国际并购咨询，首次公开发行和资金筹集。
- Guy Innes,served as a Director of Singapore Volition, a position he held from August 18, 2010 to December 15, 2015. Mr. Innes has served as a non-executive Director on the boards of mineral exploration companies such as Carbon Mining PLC and Magellan Copper & Gold PLC, both from 2007 to 2010, and on the board of ProBio Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii, from 2000 to 2006. Mr. Innes had a long career in banking and private equity, including advisory roles with Quartz Capital Partners Limited, or Quartz, a small London based investment bank specializing in new technology companies, from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including initial public offerings, private placements and mergers and acquisitions; Baring Private Equity Partners Limited, a private equity investment firm, in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Baring Brothers & Co. Limited, a London based international investment bank, in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers and acquisitions, as well as initial public offerings and capital raising. Mr. Innes is a chartered accountant and a member of the Institute of Chartered Accountants in England and Wales. Mr. Innes has extensive experience in financing and managing technology companies. Mr. Innes received a B.Sc. in Geography from Bristol University.
- Alan Colman
-
Alan Colman担任董事。在换股协议之前，2011年4月1日至2015年12月15日Cole曼博士曾担任新加坡 Volition的董事；自2011年4月5日起，担任新加坡 Volition科学顾问委员会主席。1971年，Cole曼博士获得Oxford University学士学位，1975年获得Oxford University硕士学位和Oxford University博士学位。Cole曼博士目前是Harvard University干细胞与再生生物学院的访问学者。2007年至2013年，Cole曼博士曾担任新加坡干细胞协会的执行主任。同时，2008年至2009年Cole曼博士是英国伦敦国王学院再生医学的教授。在加入A * STAR新加坡干细胞协会之前，2002年至2007年Cole曼博士是新加坡人类胚胎干细胞公司、ES细胞国际的首席科学官和首席执行官。从20世纪80年代末到2002年，Cole曼博士是英国爱丁堡PPL治疗公司的研究主管，在那里他负责领导PPL的研究方案战略，也在PPL的融资回合发挥重要的作用，1996年在伦敦证券交易所上市。1996年这家公司引起了媒体的关注，因为它的体细胞核转移技术，诞生世界上第一个成体细胞—多利克隆羊。Cole曼博士曾在伯明翰华威的Oxford University有一个成功的大学生涯，在那里他是生物化学和伦敦的教授（如上所述）。上述公司或组织没有一个是母公司、子公司或本公司其他关联公司。Cole曼博士目前的兴趣是使用诱导多能干细胞发展人类疾病模型。
Alan Colman,serves as a director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Colman served as a Director of Singapore Volition from April 1, 2011 to December 15, 2015. Dr. Colman currently serves as chairman of the Scientific Advisory Board of Belgian Volition, a position he has held since April 5, 2011. Until its acquisition by Vertex Pharmaceuticals, a biopharmaceuticals company, in October 2019, Dr. Colman served on the Scientific Advisory Board of Semma Therapeutics, Inc., a stem cell therapy company based in Cambridge, Massachusetts, a position he held since December 2014. From 2007 to 2013, Dr. Colman served as the Executive Director of the A*STAR Singapore Stem Cell Consortium, or A*STAR. Concurrently, Dr. Colman was Professor of Regenerative Medicine at king's College, London, United Kingdom, from 2008 to 2009. Prior to joining the A*STAR, Dr. Colman was Chief Scientific Officer and then Chief Executive Officer for ES Cell International, a Singaporean human embryonic stem cell company, from 2002 to 2007. Dr. Colman was the research director at PPL Therapeutics in Edinburgh, United Kingdom., or PPL, from the late 1980s until 2002, where he was responsible for leading PPL's research program strategy, also playing a role in PPL's financing rounds, culminating in its listing on the London Stock Exchange in 1996. PPL attracted considerable media attention because of its participation in the technique of somatic nuclear transfer that led to the world's first sheep cloned from an adult cell, Dolly, in 1996. Dr. Colman had a successful university career in the Universities of Oxford, Warwick, Birmingham, where he was Professor of Biochemistry, and London, as described above. Between 2014 and 2024, Dr Colman was an Associate of the Harvard University Department of Stem Cells and Regenerative Biology. Dr. Colman's main current interest is the development of human disease models Volitionrx Limited ing induced pluripotent stem cells. Dr. Colman received a B.A., M.A. and Ph.D. from Oxford University. - Alan Colman担任董事。在换股协议之前，2011年4月1日至2015年12月15日Cole曼博士曾担任新加坡 Volition的董事；自2011年4月5日起，担任新加坡 Volition科学顾问委员会主席。1971年，Cole曼博士获得Oxford University学士学位，1975年获得Oxford University硕士学位和Oxford University博士学位。Cole曼博士目前是Harvard University干细胞与再生生物学院的访问学者。2007年至2013年，Cole曼博士曾担任新加坡干细胞协会的执行主任。同时，2008年至2009年Cole曼博士是英国伦敦国王学院再生医学的教授。在加入A * STAR新加坡干细胞协会之前，2002年至2007年Cole曼博士是新加坡人类胚胎干细胞公司、ES细胞国际的首席科学官和首席执行官。从20世纪80年代末到2002年，Cole曼博士是英国爱丁堡PPL治疗公司的研究主管，在那里他负责领导PPL的研究方案战略，也在PPL的融资回合发挥重要的作用，1996年在伦敦证券交易所上市。1996年这家公司引起了媒体的关注，因为它的体细胞核转移技术，诞生世界上第一个成体细胞—多利克隆羊。Cole曼博士曾在伯明翰华威的Oxford University有一个成功的大学生涯，在那里他是生物化学和伦敦的教授（如上所述）。上述公司或组织没有一个是母公司、子公司或本公司其他关联公司。Cole曼博士目前的兴趣是使用诱导多能干细胞发展人类疾病模型。
- Alan Colman,serves as a director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Colman served as a Director of Singapore Volition from April 1, 2011 to December 15, 2015. Dr. Colman currently serves as chairman of the Scientific Advisory Board of Belgian Volition, a position he has held since April 5, 2011. Until its acquisition by Vertex Pharmaceuticals, a biopharmaceuticals company, in October 2019, Dr. Colman served on the Scientific Advisory Board of Semma Therapeutics, Inc., a stem cell therapy company based in Cambridge, Massachusetts, a position he held since December 2014. From 2007 to 2013, Dr. Colman served as the Executive Director of the A*STAR Singapore Stem Cell Consortium, or A*STAR. Concurrently, Dr. Colman was Professor of Regenerative Medicine at king's College, London, United Kingdom, from 2008 to 2009. Prior to joining the A*STAR, Dr. Colman was Chief Scientific Officer and then Chief Executive Officer for ES Cell International, a Singaporean human embryonic stem cell company, from 2002 to 2007. Dr. Colman was the research director at PPL Therapeutics in Edinburgh, United Kingdom., or PPL, from the late 1980s until 2002, where he was responsible for leading PPL's research program strategy, also playing a role in PPL's financing rounds, culminating in its listing on the London Stock Exchange in 1996. PPL attracted considerable media attention because of its participation in the technique of somatic nuclear transfer that led to the world's first sheep cloned from an adult cell, Dolly, in 1996. Dr. Colman had a successful university career in the Universities of Oxford, Warwick, Birmingham, where he was Professor of Biochemistry, and London, as described above. Between 2014 and 2024, Dr Colman was an Associate of the Harvard University Department of Stem Cells and Regenerative Biology. Dr. Colman's main current interest is the development of human disease models Volitionrx Limited ing induced pluripotent stem cells. Dr. Colman received a B.A., M.A. and Ph.D. from Oxford University.
- Timothy Still
-
Timothy Still在医疗诊断、设备和数字健康领域拥有超过35年的经验，在大型和小型公司内设计和实施高度集中的商业和业务发展战略方面拥有丰富的经验。在其职业生涯中，Still先生直接负责建立其之前所有公司的商业可行性——其中许多公司已被成功收购——并在发现新的市场机会、开发市场、筹集资金以及与战略业务合作伙伴、行业供应商、医疗保健投资银行和行业分析师发展全球关系方面拥有一致的业绩记录，同时迅速提高收入、市场份额和盈利能力。Still先生目前担任TSTILL Enterprises LLC的董事长兼首席执行官，该公司为初创和快速增长的医疗技术公司提供战略、投资和咨询咨询服务，他自2019年1月起担任该职位，目前还自2023年9月起担任Revival Healthcare，Inc.的运营合伙人，参与评估和管理医疗技术的投资机会。2021年6月至2023年2月，Still先生担任分子诊断公司Sense BioDetection Limited的总裁兼首席执行官，该公司于2023年2月与Sherlock Biosciences，Inc.合并，以创建一家服务于消费者诊断市场的领先的即时诊断公司。2008年至2021年期间，Still先生曾在多家医疗技术公司担任首席执行官和/或董事会成员：Myoscience，Inc.、MDX Health SA（NASDAQ：MDXH）、Gold Standard诊断公司（执行主席）、Global Kinetics Corporation、Xagenic，Inc.和Accumetrics，Inc.。在其职业生涯早期，Still先生还曾在HemoSense（NASDAQ：HEM）、Cholestech（NASDAQ：CTEC）和Boehringer Mannheim/Roche担任高级领导职务。Still先生目前担任Monod Bio，Inc.的董事会成员，该职位自2023年1月起担任，并分别自2023年6月、2023年7月和2024年6月起担任miDiagnostics SA、Centese，Inc.和Ramanomics Limited的董事。Mr. Still拥有加州大学生物科学（最高荣誉）学士学位，并获得南加州大学市场营销和创业工商管理硕士学位（院长学者）。
Timothy Still,has over 35 years' experience in medical diagnostics, devices and digital health, and has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Over the course of his career, Mr. Still has been directly responsible for building the commercial viability of all of his previous companies – many of which have been successfully acquired - and has a consistent track record of identifying new market opportunities, developing markets, raising capital and developing global relationships with strategic business partners, industry suppliers, healthcare investment banks and industry analysts, while rapidly increasing revenue, market share and profitability. Mr. Still currently serves as Chairman and CEO of TSTILL Enterprises LLC, a company that provides strategic, investment, and advisory consulting services for start-up and rapidly growing medical technology companies, a position he has held since January 2019, and also currently serves, since September 2023, as an Operating Partner with Revival Healthcare, Inc., where he is involved in evaluating and managing investment opportunities in medical technology. From June 2021 to February 2023, Mr. Still was President and CEO of Sense Biodetection Limited, a molecular diagnostics company, which merged with Sherlock Biosciences, Inc. in February 2023 to create a leading point-of-care diagnostics company serving the consumer diagnostics market. Between 2008 and 2021, Mr. Still has been a CEO and/or board member at numerous medical technology companies: Myoscience, Inc., MDx Health SA (NASDAQ: MDXH), Gold Standard Diagnostics, Inc. (Executive Chairman), Global Kinetics Corporation, Xagenic, Inc. and Accumetrics, Inc. Earlier in his career, Mr. Still also held senior leadership roles at HemoSense (NASDAQ: HEM), Cholestech (NASDAQ: CTEC), and Boehringer Mannheim / Roche. Mr. Still currently serves on the board of directors of Monod Bio, Inc., a position he has held since January 2023, and as a director of miDiagnostics SA, Centese, Inc., and Ramanomics Limited, since June 2023, July 2023 and June 2024, respectively. Mr. Still holds a B.S. degree in Biological Sciences (Highest Honors) from the University of California and received an M.B.A. in Marketing and Entrepreneurship (Dean's Scholar) from the University of Southern California. - Timothy Still在医疗诊断、设备和数字健康领域拥有超过35年的经验，在大型和小型公司内设计和实施高度集中的商业和业务发展战略方面拥有丰富的经验。在其职业生涯中，Still先生直接负责建立其之前所有公司的商业可行性——其中许多公司已被成功收购——并在发现新的市场机会、开发市场、筹集资金以及与战略业务合作伙伴、行业供应商、医疗保健投资银行和行业分析师发展全球关系方面拥有一致的业绩记录，同时迅速提高收入、市场份额和盈利能力。Still先生目前担任TSTILL Enterprises LLC的董事长兼首席执行官，该公司为初创和快速增长的医疗技术公司提供战略、投资和咨询咨询服务，他自2019年1月起担任该职位，目前还自2023年9月起担任Revival Healthcare，Inc.的运营合伙人，参与评估和管理医疗技术的投资机会。2021年6月至2023年2月，Still先生担任分子诊断公司Sense BioDetection Limited的总裁兼首席执行官，该公司于2023年2月与Sherlock Biosciences，Inc.合并，以创建一家服务于消费者诊断市场的领先的即时诊断公司。2008年至2021年期间，Still先生曾在多家医疗技术公司担任首席执行官和/或董事会成员：Myoscience，Inc.、MDX Health SA（NASDAQ：MDXH）、Gold Standard诊断公司（执行主席）、Global Kinetics Corporation、Xagenic，Inc.和Accumetrics，Inc.。在其职业生涯早期，Still先生还曾在HemoSense（NASDAQ：HEM）、Cholestech（NASDAQ：CTEC）和Boehringer Mannheim/Roche担任高级领导职务。Still先生目前担任Monod Bio，Inc.的董事会成员，该职位自2023年1月起担任，并分别自2023年6月、2023年7月和2024年6月起担任miDiagnostics SA、Centese，Inc.和Ramanomics Limited的董事。Mr. Still拥有加州大学生物科学（最高荣誉）学士学位，并获得南加州大学市场营销和创业工商管理硕士学位（院长学者）。
- Timothy Still,has over 35 years' experience in medical diagnostics, devices and digital health, and has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Over the course of his career, Mr. Still has been directly responsible for building the commercial viability of all of his previous companies – many of which have been successfully acquired - and has a consistent track record of identifying new market opportunities, developing markets, raising capital and developing global relationships with strategic business partners, industry suppliers, healthcare investment banks and industry analysts, while rapidly increasing revenue, market share and profitability. Mr. Still currently serves as Chairman and CEO of TSTILL Enterprises LLC, a company that provides strategic, investment, and advisory consulting services for start-up and rapidly growing medical technology companies, a position he has held since January 2019, and also currently serves, since September 2023, as an Operating Partner with Revival Healthcare, Inc., where he is involved in evaluating and managing investment opportunities in medical technology. From June 2021 to February 2023, Mr. Still was President and CEO of Sense Biodetection Limited, a molecular diagnostics company, which merged with Sherlock Biosciences, Inc. in February 2023 to create a leading point-of-care diagnostics company serving the consumer diagnostics market. Between 2008 and 2021, Mr. Still has been a CEO and/or board member at numerous medical technology companies: Myoscience, Inc., MDx Health SA (NASDAQ: MDXH), Gold Standard Diagnostics, Inc. (Executive Chairman), Global Kinetics Corporation, Xagenic, Inc. and Accumetrics, Inc. Earlier in his career, Mr. Still also held senior leadership roles at HemoSense (NASDAQ: HEM), Cholestech (NASDAQ: CTEC), and Boehringer Mannheim / Roche. Mr. Still currently serves on the board of directors of Monod Bio, Inc., a position he has held since January 2023, and as a director of miDiagnostics SA, Centese, Inc., and Ramanomics Limited, since June 2023, July 2023 and June 2024, respectively. Mr. Still holds a B.S. degree in Biological Sciences (Highest Honors) from the University of California and received an M.B.A. in Marketing and Entrepreneurship (Dean's Scholar) from the University of Southern California.
- Phillip Barnes
-
菲利普·巴恩斯，目前已退役。2009年至2016年期间，他曾在英国National Health服务（NHS）多家医院的董事会任职，担任首席医疗官和首席执行官。Barnes博士还参与了NHS和制药行业的多个国家和地区咨询小组。在担任医师主管之前，巴恩斯博士于1995年至2009年期间担任伦敦国王学院医院的顾问神经学家，并于1999年至2009年期间担任伦敦国王学院神经病学高级讲师Hon.。他在1995年至1998年期间担任神经病学临床主任，担任管理和行政职务，1998年至2008年担任英国最大的区域神经科学中心国王神经科学中心的服务主任。Barnes博士获得了基础医学科学学士学位、伦敦大学解剖学和神经内分泌学博士学位以及牛津大学临床医学学位（B.M. B.CH.）。
Phillip Barnes,is currently retired. Between 2009 and 2016, he served on the Board of Directors of a number of United Kingdom National Health Service, or NHS, hospitals both as Chief Medical Officer and Chief Executive Officer. Dr. Barnes wasalso involved in a number of national and regional advisory groups for the NHS and pharmaceutical industry. Prior to his career as a physician executive, Dr. Barnes was Consultant Neurologist at King's College Hospital, London between 1995 and 2009, and Hon. Senior Lecturer in Neurology at King's College London between 1999 and 2009. He served as Clinical Director for Neurology, a managerial and administrative role, between 1995 and 1998, and from 1998 until 2008 was Chief of Service of the King's Neurosciences Centre, the United Kingdom's largest Regional Neuroscience Centre. Dr. Barnes received a B.Sc. in Basic Medical Sciences, a Ph.D. in Anatomy and Neuroendocrinology from the University of London and a clinical medical degree (B.M. B.Ch.) from the University of Oxford. - 菲利普·巴恩斯，目前已退役。2009年至2016年期间，他曾在英国National Health服务（NHS）多家医院的董事会任职，担任首席医疗官和首席执行官。Barnes博士还参与了NHS和制药行业的多个国家和地区咨询小组。在担任医师主管之前，巴恩斯博士于1995年至2009年期间担任伦敦国王学院医院的顾问神经学家，并于1999年至2009年期间担任伦敦国王学院神经病学高级讲师Hon.。他在1995年至1998年期间担任神经病学临床主任，担任管理和行政职务，1998年至2008年担任英国最大的区域神经科学中心国王神经科学中心的服务主任。Barnes博士获得了基础医学科学学士学位、伦敦大学解剖学和神经内分泌学博士学位以及牛津大学临床医学学位（B.M. B.CH.）。
- Phillip Barnes,is currently retired. Between 2009 and 2016, he served on the Board of Directors of a number of United Kingdom National Health Service, or NHS, hospitals both as Chief Medical Officer and Chief Executive Officer. Dr. Barnes wasalso involved in a number of national and regional advisory groups for the NHS and pharmaceutical industry. Prior to his career as a physician executive, Dr. Barnes was Consultant Neurologist at King's College Hospital, London between 1995 and 2009, and Hon. Senior Lecturer in Neurology at King's College London between 1999 and 2009. He served as Clinical Director for Neurology, a managerial and administrative role, between 1995 and 1998, and from 1998 until 2008 was Chief of Service of the King's Neurosciences Centre, the United Kingdom's largest Regional Neuroscience Centre. Dr. Barnes received a B.Sc. in Basic Medical Sciences, a Ph.D. in Anatomy and Neuroendocrinology from the University of London and a clinical medical degree (B.M. B.Ch.) from the University of Oxford.
- Mickie Henshall
-
Mickie Henshall，担任Tempus全资子公司Ambry Genetics的首席商务官。Henshall女士自2025年1月起担任现任职务，负责临床基因组学检测公司的商业运营、产品管理、市场营销和市场准入部门。在担任此职务之前，2020年10月至2025年1月，Henshall女士担任REALM IDX，Inc.（前身为Konica Minolta Precision Medicine）的首席营销官，该公司是Ambry Genetics Corporation和Invicro，LLC的前母公司，后者专注于通过将基因组学、成像、放射学和病理学与先进的人工智能结合，开发创新的医疗保健解决方案，从而在集成诊断领域取得开创性发展。Henshall女士负责企业更名和品牌重塑、重组营销组织、支持公司的商业扩张和实施正式的产品开发流程，最终导致Ambry和Invicro业务的成功退出。在加入REALM IDX之前，从2020年4月到2020年10月，Henshall女士担任Genomic Life，Inc.的首席营销官，该公司是一家专注于扩大精准医疗服务的健康服务公司。她负责公司的付费福利计划Cancer Guardian的公司战略和营销，该计划为被诊断患有癌症的人提供遗传风险洞察和全面的基因组分析支持服务。在此之前，从2017年到2020年4月，Henshall女士担任Agena Bioscience（现为Mesa Laboratories, Inc.（纳斯达克股票代码：MLAB）的一部分）的营销副总裁，该公司是一家分子诊断公司，提供用于遗传疾病和变异谱分析的靶向分析的仪器系统和分析。Henshall女士领导了Agena的企业营销、产品管理、科学事务、定制检测服务，以及中国、澳大利亚和德国的区域营销团队。2014年至2017年期间，Henshall女士在Accriva Diagnostics，Inc.或Accriva担任营销副总裁，这是一家专注于医院的即时心血管诊断公司，在那里她建立了一个新的营销团队，开发了Accriva即时诊断产品的品牌重塑，制定了一个五年投资组合路线图，并为准备将Accriva出售给Werfen Life提供了支持。从2010年到2014年，Henshall女士担任实验室耗材供应商Biotix，Inc的营销副总裁，负责管理全球营销计划的各个方面，包括企业品牌、渠道营销、公共关系和销售培训。从2005年到2010年，Henshall女士在基因组技术的全球领导者Illumina, Inc.（纳斯达克股票代码：ILMN）担任越来越多的领导职务，在那里她通过许多首创为公司提供了支持，包括制定其第一个诊断组合战略、召开其第一个诊断顾问委员会、加入其第一个诊断营销团队，以及开发和推出其第一个FDA批准的系统。Henshall女士是一名营销主管，在为IVD、临床和生命科学市场制定和实施营销和销售策略方面拥有超过20年的经验。Henshall女士拥有加州大学伯克利分校综合生物学学士学位。
Mickie Henshall,serves as Chief Business Officer of Ambry Genetics, a wholly owned subsidiary of Tempus. In her current role, which she has held since January 2025, Ms. Henshall is responsible for the Commercial Operations, Product Management, Marketing and Market Access departments for the clinical genomics testing company. Prior to this role, from October 2020 to January 2025, Ms. Henshall was the Chief Marketing Officer of REALM IDx, Inc. (formerly Konica Minolta Precision Medicine), and the former parent company of Ambry Genetics Corporation and Invicro, LLC, which was focused on pioneering developments in the field of integrated diagnostics by uniting genomics, imaging, radiology and pathology with advanced artificial intelligence to develop innovative healthcare solutions. Ms. Henshall was responsible for the corporate name change and rebranding, restructuring the marketing organization, supporting the company's commercial expansion and implementing formal product development processes, ultimately leading to the successful exits of both the Ambry and Invicro businesses. Prior to joining REALM IDx, from April 2020 to October 2020, Ms. Henshall served as Chief Marketing Officer of Genomic Life, Inc., a health services company focused on expanding access to precision medicine. She was responsible for corporate strategy and marketing of the company's paid benefit program, Cancer Guardian, which provides genetic risk insights and comprehensive genomic profiling with support services for those diagnosed with cancer. Prior to that, from 2017 to April 2020, Ms. Henshall was Vice President of Marketing at Agena Bioscience (now part of Mesa Laboratories, Inc. (NASDAQ: MLAB)), a molecular diagnostics company delivering instrument systems and assays for targeted analysis of genetic disease and variant profiling. Ms. Henshall led Agena's Corporate Marketing, Product Management, Scientific Affairs, Custom Assay Services, and the regional marketing teams in China, Australia, and Germany. Between 2014 and 2017, Ms. Henshall served as Vice President of Marketing at Accriva Diagnostics, Inc., or Accriva, a hospital-focused, point-of-care cardiovascular diagnostics company, where she established a new marketing team, developed re-branding of Accriva's point-of-care diagnostics products, generated a five-year portfolio roadmap and provided support in preparing Accriva for sale to Werfen Life. From 2010 to 2014, Ms. Henshall was Vice President of Marketing at Biotix, Inc, a supplier of laboratory consumables, where she managed all aspects of global marketing initiatives, including corporate branding, channel marketing, public relations, and sales training. From 2005 to 2010, Ms. Henshall had increasing levels of leadership roles at Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic technologies, where she supported the company through many firsts, including developing its first diagnostic portfolio strategy, convening its first Diagnostic Advisory Board, onboarding its first diagnostics marketing team, and development and launch of its first FDA cleared system. Ms. Henshall is a marketing executive with over 20 years' experience in developing and implementing marketing and sales strategies for the IVD, clinical and life science markets. Ms. Henshall holds a B.S. in Integrative Biology from the University of California, Berkeley. - Mickie Henshall，担任Tempus全资子公司Ambry Genetics的首席商务官。Henshall女士自2025年1月起担任现任职务，负责临床基因组学检测公司的商业运营、产品管理、市场营销和市场准入部门。在担任此职务之前，2020年10月至2025年1月，Henshall女士担任REALM IDX，Inc.（前身为Konica Minolta Precision Medicine）的首席营销官，该公司是Ambry Genetics Corporation和Invicro，LLC的前母公司，后者专注于通过将基因组学、成像、放射学和病理学与先进的人工智能结合，开发创新的医疗保健解决方案，从而在集成诊断领域取得开创性发展。Henshall女士负责企业更名和品牌重塑、重组营销组织、支持公司的商业扩张和实施正式的产品开发流程，最终导致Ambry和Invicro业务的成功退出。在加入REALM IDX之前，从2020年4月到2020年10月，Henshall女士担任Genomic Life，Inc.的首席营销官，该公司是一家专注于扩大精准医疗服务的健康服务公司。她负责公司的付费福利计划Cancer Guardian的公司战略和营销，该计划为被诊断患有癌症的人提供遗传风险洞察和全面的基因组分析支持服务。在此之前，从2017年到2020年4月，Henshall女士担任Agena Bioscience（现为Mesa Laboratories, Inc.（纳斯达克股票代码：MLAB）的一部分）的营销副总裁，该公司是一家分子诊断公司，提供用于遗传疾病和变异谱分析的靶向分析的仪器系统和分析。Henshall女士领导了Agena的企业营销、产品管理、科学事务、定制检测服务，以及中国、澳大利亚和德国的区域营销团队。2014年至2017年期间，Henshall女士在Accriva Diagnostics，Inc.或Accriva担任营销副总裁，这是一家专注于医院的即时心血管诊断公司，在那里她建立了一个新的营销团队，开发了Accriva即时诊断产品的品牌重塑，制定了一个五年投资组合路线图，并为准备将Accriva出售给Werfen Life提供了支持。从2010年到2014年，Henshall女士担任实验室耗材供应商Biotix，Inc的营销副总裁，负责管理全球营销计划的各个方面，包括企业品牌、渠道营销、公共关系和销售培训。从2005年到2010年，Henshall女士在基因组技术的全球领导者Illumina, Inc.（纳斯达克股票代码：ILMN）担任越来越多的领导职务，在那里她通过许多首创为公司提供了支持，包括制定其第一个诊断组合战略、召开其第一个诊断顾问委员会、加入其第一个诊断营销团队，以及开发和推出其第一个FDA批准的系统。Henshall女士是一名营销主管，在为IVD、临床和生命科学市场制定和实施营销和销售策略方面拥有超过20年的经验。Henshall女士拥有加州大学伯克利分校综合生物学学士学位。
- Mickie Henshall,serves as Chief Business Officer of Ambry Genetics, a wholly owned subsidiary of Tempus. In her current role, which she has held since January 2025, Ms. Henshall is responsible for the Commercial Operations, Product Management, Marketing and Market Access departments for the clinical genomics testing company. Prior to this role, from October 2020 to January 2025, Ms. Henshall was the Chief Marketing Officer of REALM IDx, Inc. (formerly Konica Minolta Precision Medicine), and the former parent company of Ambry Genetics Corporation and Invicro, LLC, which was focused on pioneering developments in the field of integrated diagnostics by uniting genomics, imaging, radiology and pathology with advanced artificial intelligence to develop innovative healthcare solutions. Ms. Henshall was responsible for the corporate name change and rebranding, restructuring the marketing organization, supporting the company's commercial expansion and implementing formal product development processes, ultimately leading to the successful exits of both the Ambry and Invicro businesses. Prior to joining REALM IDx, from April 2020 to October 2020, Ms. Henshall served as Chief Marketing Officer of Genomic Life, Inc., a health services company focused on expanding access to precision medicine. She was responsible for corporate strategy and marketing of the company's paid benefit program, Cancer Guardian, which provides genetic risk insights and comprehensive genomic profiling with support services for those diagnosed with cancer. Prior to that, from 2017 to April 2020, Ms. Henshall was Vice President of Marketing at Agena Bioscience (now part of Mesa Laboratories, Inc. (NASDAQ: MLAB)), a molecular diagnostics company delivering instrument systems and assays for targeted analysis of genetic disease and variant profiling. Ms. Henshall led Agena's Corporate Marketing, Product Management, Scientific Affairs, Custom Assay Services, and the regional marketing teams in China, Australia, and Germany. Between 2014 and 2017, Ms. Henshall served as Vice President of Marketing at Accriva Diagnostics, Inc., or Accriva, a hospital-focused, point-of-care cardiovascular diagnostics company, where she established a new marketing team, developed re-branding of Accriva's point-of-care diagnostics products, generated a five-year portfolio roadmap and provided support in preparing Accriva for sale to Werfen Life. From 2010 to 2014, Ms. Henshall was Vice President of Marketing at Biotix, Inc, a supplier of laboratory consumables, where she managed all aspects of global marketing initiatives, including corporate branding, channel marketing, public relations, and sales training. From 2005 to 2010, Ms. Henshall had increasing levels of leadership roles at Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic technologies, where she supported the company through many firsts, including developing its first diagnostic portfolio strategy, convening its first Diagnostic Advisory Board, onboarding its first diagnostics marketing team, and development and launch of its first FDA cleared system. Ms. Henshall is a marketing executive with over 20 years' experience in developing and implementing marketing and sales strategies for the IVD, clinical and life science markets. Ms. Henshall holds a B.S. in Integrative Biology from the University of California, Berkeley.
- Kim Nguyen
-
Kim Nguyen，现任优步亚太区人力资源或亚太区人力资源总监，自2024年6月起担任该职位。在2023年11月至2024年5月期间，Nguyen女士担任伦敦证券交易所集团亚太区人力资源集团董事。在2022年1月至2023年11月期间，Nguyen女士担任区块链公司Binance的国际人力资源副总裁。2017年9月和2022年1月，Nguyen女士担任Google Asia Pacific Pte.Ltd.的人力资源主管。在此之前，Nguyen女士于2007年4月至2017年9月在Google UK Limited工作，在欧洲和拉丁美洲的技术和销售部门担任多个职位。Nguyen女士的人力资源职业生涯跨越20多年，从事科技、金融科技和金融服务业务。她建立并领导了大型团队，推动业务转型、企业重组、劳动力规划、危机管理、并购，以及推动新市场扩张的人力资源战略。她曾在所有国际市场工作，帮助企业在全球环境中驾驭文化和人才需求，同时满足当地劳动法要求。凭借在跨国和初创环境中的经验，她可以胜任地在更成熟的环境中运营，或者从头开始构建结构和程序。Nguyen女士获得了澳大利亚悉尼新南威尔士大学心理学荣誉学士学位。
Kim Nguyen,is currently a Director, Asia Pacific Human Resources, or APAC HR, for Uber Technologies, a position she has held since June 2024. Between November 2023 and May 2024, Ms. Nguyen served as Group Director, Asia Pacific Human Resources for the London Stock Exchange Group. Between January 2022 and November 2023, Ms. Nguyen served as Vice President of International HR of Binance, a blockchain company. From September 2017 and January 2022, Ms. Nguyen served as Head of HR for Google Asia Pacific Pte. Ltd. Prior to that, Ms. Nguyen worked with Google UK Limited from April 2007 to September 2017, where she held a number of positions working across the Technology and Sales divisions across Europe and Latin America. Ms. Nguyen's HR career spans over 20 years in Technology, FinTech and Financial Services businesses. She has built and led large teams driving business transformation, corporate reorganization, workforce planning, crisis management, mergers and acquisitions, as well as driving HR strategy for new market expansion. She has worked across all international markets and has helped companies navigate culture and talent needs in a global setting, while meeting local labour law requirements. With experience in both multinational and start up environments she can competently operate in more established environments or build structures and programs from the ground up. Ms. Nguyen received a B.S. in Psychology Honors from the University of New South Wales, Sydney, Australia. - Kim Nguyen，现任优步亚太区人力资源或亚太区人力资源总监，自2024年6月起担任该职位。在2023年11月至2024年5月期间，Nguyen女士担任伦敦证券交易所集团亚太区人力资源集团董事。在2022年1月至2023年11月期间，Nguyen女士担任区块链公司Binance的国际人力资源副总裁。2017年9月和2022年1月，Nguyen女士担任Google Asia Pacific Pte.Ltd.的人力资源主管。在此之前，Nguyen女士于2007年4月至2017年9月在Google UK Limited工作，在欧洲和拉丁美洲的技术和销售部门担任多个职位。Nguyen女士的人力资源职业生涯跨越20多年，从事科技、金融科技和金融服务业务。她建立并领导了大型团队，推动业务转型、企业重组、劳动力规划、危机管理、并购，以及推动新市场扩张的人力资源战略。她曾在所有国际市场工作，帮助企业在全球环境中驾驭文化和人才需求，同时满足当地劳动法要求。凭借在跨国和初创环境中的经验，她可以胜任地在更成熟的环境中运营，或者从头开始构建结构和程序。Nguyen女士获得了澳大利亚悉尼新南威尔士大学心理学荣誉学士学位。
- Kim Nguyen,is currently a Director, Asia Pacific Human Resources, or APAC HR, for Uber Technologies, a position she has held since June 2024. Between November 2023 and May 2024, Ms. Nguyen served as Group Director, Asia Pacific Human Resources for the London Stock Exchange Group. Between January 2022 and November 2023, Ms. Nguyen served as Vice President of International HR of Binance, a blockchain company. From September 2017 and January 2022, Ms. Nguyen served as Head of HR for Google Asia Pacific Pte. Ltd. Prior to that, Ms. Nguyen worked with Google UK Limited from April 2007 to September 2017, where she held a number of positions working across the Technology and Sales divisions across Europe and Latin America. Ms. Nguyen's HR career spans over 20 years in Technology, FinTech and Financial Services businesses. She has built and led large teams driving business transformation, corporate reorganization, workforce planning, crisis management, mergers and acquisitions, as well as driving HR strategy for new market expansion. She has worked across all international markets and has helped companies navigate culture and talent needs in a global setting, while meeting local labour law requirements. With experience in both multinational and start up environments she can competently operate in more established environments or build structures and programs from the ground up. Ms. Nguyen received a B.S. in Psychology Honors from the University of New South Wales, Sydney, Australia.
- Ethel Rubin
-
Ethel Rubin在领导全球大型企业以及早期运营的医疗保健创新和商业化战略方面拥有超过20年的经验。在她的职业生涯中，鲁宾博士为市场上超过25种商业产品做出了贡献，包括诊断、治疗、SaaS和设备，并在多项并购、合作伙伴关系、合作和战略举措中发挥了重要作用。鲁宾博士目前担任BioHealth Innovation，Inc.的风险投资主管，她自2015年5月以来一直担任该职位。在这个职位上，鲁宾博士领导着一个战略和财务顾问团队，他们帮助企业制定实现商业目标和估值拐点的战略，还为企业与私人资本做好准备并建立联系。在她受雇于BioHealth Innovation的早期，从2015年5月到2018年8月，鲁宾博士负责领导美国国立卫生研究院加速创新中心的早期投资，部署了一个4500万美元的基金，该基金投资于多个平台技术和治疗资产，这些资产后来筹集或退出了超过10亿美元。鲁宾博士目前还从2021年4月开始兼职，担任Mirabile Lifesci Advisory，LLC的总裁兼首席执行官，该公司在与战略和财务规划、合作与联盟以及技术开发相关的领域为生命科学公司的首席执行官提供建议。从2009年11月到2015年8月，鲁宾博士在心血管集团美敦力，PLC，担任外部创新、全球临床战略和医疗事务等领域的多重领导职务，在那里她指导了资金和/或参与了100多项临床试验和研究。2008年6月至2009年5月，鲁宾博士担任CSA医疗公司（现为Steris Healthcare，纽约证券交易所代码：STE）的首席科学官，并于2004年6月和2008年6月担任BioFortis，Inc.（于2018年被艾昆纬旗下Q2 Solutions公司（纽约证券交易所代码：IQV）收购）的首席科学与运营官，在那里她在这些公司的技术开发和商业化努力中发挥了关键作用。2020年2月至2023年2月期间，鲁宾博士曾在新生儿医疗器械公司Innara Health，Inc.的董事会任职，在此期间，Innara完成了A轮融资，并于2023年出售给了卡地纳健康（纽约证券交易所代码：CAH）。鲁宾博士还在2006年5月至2008年5月期间担任非营利性技术孵化器Emerging Technology Centers，Inc.的董事，在那里她支持该中心在生命科学领域的发展。鲁宾博士拥有罗切斯特大学的生物化学学士学位，并获得罗切斯特大学医学和牙科学院的生物化学和生物物理学博士学位。
Ethel Rubin,has over 20 years' experience leading healthcare innovation and commercialization strategies for both large global corporates as well as early-stage operations. Over the course of her career, Dr. Rubin contributed to over 25 commercial products in the market, ranging from diagnostics, therapeutics, SaaS and devices, and was instrumental in multiple mergers and acquisitions, partnerships, collaborations and strategic initiatives. Dr. Rubin currently serves as Head of Ventures for BioHealth Innovation, Inc., a position she has held since May 2015. In this role, Dr. Rubin leads a team of strategy and finance consultants who help companies develop strategies that achieve commercial goals and valuation inflection points and who also prepare and connect companies with private capital. Earlier in her employment with BioHealth Innovation, from May 2015 to August 2018, Dr. Rubin was responsible for leading early investments for the NIH Centers for Accelerated Innovation, deploying a $45 million fund, which invested in multiple platform technologies and therapeutic assets that have gone on to raise or exit for over $1 billion. Dr. Rubin also currently serves on a part-time basis since April 2021, as President and CEO of Mirabile Lifesci Advisory, LLC, which advises CEOs of lifesciences companies in areas related to strategic and financial planning, partnering & alliances, and technology development. From November 2009 to August 2015, Dr. Rubin held multiple leadership roles in areas such as external innovation, global clinical strategy and medical affairs at Medtronic, plc, Cardiovascular Group, where she directed the funding and/or was involved in over 100 clinical trials and research studies. Between June 2008 to May 2009, Dr. Rubin was Chief Scientific Officer of CSA Medical, Inc. (now Steris Healthcare, NYSE: STE), and from June 2004 and June 2008 was Chief Scientific & Operations Officer of BioFortis, Inc. (acquired by Q2 Solutions, an IQVIA company (NYSE: IQV), in 2018), where she played key roles in technology development and commercialization efforts for these companies. Between February 2020 and February 2023, Dr. Rubin served on the board of directors of Innara Health, Inc., a neonatal medical device company, during which time Innara completed a Series A financing and a sale to Cardinal Health in 2023 (NYSE: CAH). Dr. Rubin also served as a director of Emerging Technology Centers, Inc., a non-profit technology incubator, between May 2006 and May 2008 where she supported the center's growth in the lifesciences space. Dr. Rubin holds a B.S. in Biochemistry from the University of Rochester and received a Ph.D. in Biochemistry and Biophysics from the University of Rochester School of Medicine and Dentistry. - Ethel Rubin在领导全球大型企业以及早期运营的医疗保健创新和商业化战略方面拥有超过20年的经验。在她的职业生涯中，鲁宾博士为市场上超过25种商业产品做出了贡献，包括诊断、治疗、SaaS和设备，并在多项并购、合作伙伴关系、合作和战略举措中发挥了重要作用。鲁宾博士目前担任BioHealth Innovation，Inc.的风险投资主管，她自2015年5月以来一直担任该职位。在这个职位上，鲁宾博士领导着一个战略和财务顾问团队，他们帮助企业制定实现商业目标和估值拐点的战略，还为企业与私人资本做好准备并建立联系。在她受雇于BioHealth Innovation的早期，从2015年5月到2018年8月，鲁宾博士负责领导美国国立卫生研究院加速创新中心的早期投资，部署了一个4500万美元的基金，该基金投资于多个平台技术和治疗资产，这些资产后来筹集或退出了超过10亿美元。鲁宾博士目前还从2021年4月开始兼职，担任Mirabile Lifesci Advisory，LLC的总裁兼首席执行官，该公司在与战略和财务规划、合作与联盟以及技术开发相关的领域为生命科学公司的首席执行官提供建议。从2009年11月到2015年8月，鲁宾博士在心血管集团美敦力，PLC，担任外部创新、全球临床战略和医疗事务等领域的多重领导职务，在那里她指导了资金和/或参与了100多项临床试验和研究。2008年6月至2009年5月，鲁宾博士担任CSA医疗公司（现为Steris Healthcare，纽约证券交易所代码：STE）的首席科学官，并于2004年6月和2008年6月担任BioFortis，Inc.（于2018年被艾昆纬旗下Q2 Solutions公司（纽约证券交易所代码：IQV）收购）的首席科学与运营官，在那里她在这些公司的技术开发和商业化努力中发挥了关键作用。2020年2月至2023年2月期间，鲁宾博士曾在新生儿医疗器械公司Innara Health，Inc.的董事会任职，在此期间，Innara完成了A轮融资，并于2023年出售给了卡地纳健康（纽约证券交易所代码：CAH）。鲁宾博士还在2006年5月至2008年5月期间担任非营利性技术孵化器Emerging Technology Centers，Inc.的董事，在那里她支持该中心在生命科学领域的发展。鲁宾博士拥有罗切斯特大学的生物化学学士学位，并获得罗切斯特大学医学和牙科学院的生物化学和生物物理学博士学位。
- Ethel Rubin,has over 20 years' experience leading healthcare innovation and commercialization strategies for both large global corporates as well as early-stage operations. Over the course of her career, Dr. Rubin contributed to over 25 commercial products in the market, ranging from diagnostics, therapeutics, SaaS and devices, and was instrumental in multiple mergers and acquisitions, partnerships, collaborations and strategic initiatives. Dr. Rubin currently serves as Head of Ventures for BioHealth Innovation, Inc., a position she has held since May 2015. In this role, Dr. Rubin leads a team of strategy and finance consultants who help companies develop strategies that achieve commercial goals and valuation inflection points and who also prepare and connect companies with private capital. Earlier in her employment with BioHealth Innovation, from May 2015 to August 2018, Dr. Rubin was responsible for leading early investments for the NIH Centers for Accelerated Innovation, deploying a $45 million fund, which invested in multiple platform technologies and therapeutic assets that have gone on to raise or exit for over $1 billion. Dr. Rubin also currently serves on a part-time basis since April 2021, as President and CEO of Mirabile Lifesci Advisory, LLC, which advises CEOs of lifesciences companies in areas related to strategic and financial planning, partnering & alliances, and technology development. From November 2009 to August 2015, Dr. Rubin held multiple leadership roles in areas such as external innovation, global clinical strategy and medical affairs at Medtronic, plc, Cardiovascular Group, where she directed the funding and/or was involved in over 100 clinical trials and research studies. Between June 2008 to May 2009, Dr. Rubin was Chief Scientific Officer of CSA Medical, Inc. (now Steris Healthcare, NYSE: STE), and from June 2004 and June 2008 was Chief Scientific & Operations Officer of BioFortis, Inc. (acquired by Q2 Solutions, an IQVIA company (NYSE: IQV), in 2018), where she played key roles in technology development and commercialization efforts for these companies. Between February 2020 and February 2023, Dr. Rubin served on the board of directors of Innara Health, Inc., a neonatal medical device company, during which time Innara completed a Series A financing and a sale to Cardinal Health in 2023 (NYSE: CAH). Dr. Rubin also served as a director of Emerging Technology Centers, Inc., a non-profit technology incubator, between May 2006 and May 2008 where she supported the center's growth in the lifesciences space. Dr. Rubin holds a B.S. in Biochemistry from the University of Rochester and received a Ph.D. in Biochemistry and Biophysics from the University of Rochester School of Medicine and Dentistry.
高管简历
中英对照 | 中文 | 英文- Cameron Reynolds
Cameron Reynolds是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
Cameron Reynolds was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX:OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds'main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC;Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V:CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V:HBY).- Cameron Reynolds是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
- Cameron Reynolds was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX:OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds'main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC;Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V:CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V:HBY).
- Rodney Rootsaert
Rodney Rootsaert，本公司秘书。在2011年9月26日本公司，后来以股东Standard Capital Corporation的名义，与Singapore Volition及其股东的换股协议签署完成之前，他从2010年8月6日起，担任Singapore Volition的行政与法律官。2007年至今，他一直担任Mining House Ltd.的董事、秘书，他的职责是确保公司的业务活动符合法定、监管方面的所有要求。2007-2011，他曾担任Magellan Copper and Gold Plc的秘书，他的职责是维护并准备公司文件、客户、合同。
Rodney Rootsaert,was the Administration and Legal Officer of Singapore Volition, a position he held since August 6, 2010. Mr. Rootsaert became a Director of Singapore Volition on December 15, 2015. He has been a Director and Secretary of Belgian Volition since October 4, 2010, a Director of Volition Diagnostics since November 13, 2015, Secretary of Volition Vet since August 7, 2019, and Secretary of Volition America since November 16, 2021. Between August 7, 2019 and March 17, 2023, Mr. Rootsaert served as Treasurer of Volition Vet. Mr. Rootsaert served as director and corporate secretary of Mining House Ltd., a company providing consultancy and office support services, between 2007 and 2018. His responsibilities included ensuring compliance with all relevant statutory and regulatory requirements. From 2007 until 2011, Mr. Rootsaert served as corporate secretary for Magellan Copper and Gold Plc., a mineral exploration company, where his duties included maintaining and preparing company documents, accounts and contracts. Mr. Rootsaert has over 15 years of experience in providing corporate, legal and administrative services. Mr. Rootsaert holds an LL.B. degree from the University of Western Australia.- Rodney Rootsaert，本公司秘书。在2011年9月26日本公司，后来以股东Standard Capital Corporation的名义，与Singapore Volition及其股东的换股协议签署完成之前，他从2010年8月6日起，担任Singapore Volition的行政与法律官。2007年至今，他一直担任Mining House Ltd.的董事、秘书，他的职责是确保公司的业务活动符合法定、监管方面的所有要求。2007-2011，他曾担任Magellan Copper and Gold Plc的秘书，他的职责是维护并准备公司文件、客户、合同。
- Rodney Rootsaert,was the Administration and Legal Officer of Singapore Volition, a position he held since August 6, 2010. Mr. Rootsaert became a Director of Singapore Volition on December 15, 2015. He has been a Director and Secretary of Belgian Volition since October 4, 2010, a Director of Volition Diagnostics since November 13, 2015, Secretary of Volition Vet since August 7, 2019, and Secretary of Volition America since November 16, 2021. Between August 7, 2019 and March 17, 2023, Mr. Rootsaert served as Treasurer of Volition Vet. Mr. Rootsaert served as director and corporate secretary of Mining House Ltd., a company providing consultancy and office support services, between 2007 and 2018. His responsibilities included ensuring compliance with all relevant statutory and regulatory requirements. From 2007 until 2011, Mr. Rootsaert served as corporate secretary for Magellan Copper and Gold Plc., a mineral exploration company, where his duties included maintaining and preparing company documents, accounts and contracts. Mr. Rootsaert has over 15 years of experience in providing corporate, legal and administrative services. Mr. Rootsaert holds an LL.B. degree from the University of Western Australia.
- Jacob Micallef
Jacob Micallef，担任公司的首席科学官，也作为首席科学官。他也曾担任Belgian Volition的董事（2011年8月10日至2016年3月31日）。达成共享交换协议之前，他曾担任Belgian Volition的高级执行官（2010年10月11日以来），但不参与Singapore Volition。他于2004年加入Cronos Therapeutics Limited（Cronos，并于2006年在英国上市，成为Valirx plc）。他继续担任Valirx plc的技术官，在那里他注册the HyperGenomics 、Nucleosomics 技术，并共同创立ValiBio SA（现称为Belgian Volition）。2004年至2007年，他曾向CASS Business School的4个学校的科学研究人员教授科学和企业课程（加入Cronos公司之前）。他于2001年共同创立Gene Expression Technologies，并于1999年获得他自己的工商管理硕士学位，在那里他曾成功领导GeneICE技术的化学开发，以及实现GeneICE分子制造。他也曾领导GeneICE公司与Bayer AG的合同业务开发和采购。15年期间，他于1985年开始任职the World Health Organization（WHO）。任职the WHO期间，他曾开发生殖健康和癌症领域的新诊断产品。他于1990年开始开发WHO的一种新的诊断技术平台（于1992年推出），并支持13测试。他还发起和实施内部生产，此前外包给Abbott Diagnostics Inc.，以及WHO的这些产品的全球分销。他于1990年创立Immunometrics Ltd.（一个非营利WHO公司，世界各地销售和分销这些诊断产品）。
Jacob Micallef,served as a Director of Belgian Volition between August 10, 2011 and March 31, 2016. Prior to the Share Exchange Agreement, he served as Chief Scientific Officer of Belgian Volition from October 11, 2010 to December 31, 2014, but was not otherwise involved with Singapore Volition. Dr. Micallef joined Cronos Therapeutics Limited, or Cronos, a company developing oncology drugs, in 2004, and in 2006, Cronos was listed in the United Kingdom on the Alternative Investment Market, or AIM, becoming ValiRx plc, or ValiRx (AIM:VAL). Dr. Micallef continued to work as Technical Officer for ValiRx, where he in-licensed the NucleosomicsTM technology and co-founded ValiBio SA, which is now Belgian Volition. From 2004 to 2007, he taught "science and enterprise" to science research workers from four universities at CASS Business School before joining Cronos. In 2001, Dr. Micallef co-founded Gene Expression Technologies, a company developing oncology drugs, where he successfully led the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer AG. Over a 15-year period, starting in 1985, Dr. Micallef worked for the World Health Organization, or WHO. While working for WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990, he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture, previously outsourced to Abbott Diagnostics Inc., and world-wide distribution of these products for WHO. Also, in 1990, he started a "not-for-profit" WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide. Dr. Micallef has over 20 years of experience in research and development and in the management of early-stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations. Dr. Micallef received his M.B.A. from Imperial College, University of London and his Ph.D. from King's College, University of London.- Jacob Micallef，担任公司的首席科学官，也作为首席科学官。他也曾担任Belgian Volition的董事（2011年8月10日至2016年3月31日）。达成共享交换协议之前，他曾担任Belgian Volition的高级执行官（2010年10月11日以来），但不参与Singapore Volition。他于2004年加入Cronos Therapeutics Limited（Cronos，并于2006年在英国上市，成为Valirx plc）。他继续担任Valirx plc的技术官，在那里他注册the HyperGenomics 、Nucleosomics 技术，并共同创立ValiBio SA（现称为Belgian Volition）。2004年至2007年，他曾向CASS Business School的4个学校的科学研究人员教授科学和企业课程（加入Cronos公司之前）。他于2001年共同创立Gene Expression Technologies，并于1999年获得他自己的工商管理硕士学位，在那里他曾成功领导GeneICE技术的化学开发，以及实现GeneICE分子制造。他也曾领导GeneICE公司与Bayer AG的合同业务开发和采购。15年期间，他于1985年开始任职the World Health Organization（WHO）。任职the WHO期间，他曾开发生殖健康和癌症领域的新诊断产品。他于1990年开始开发WHO的一种新的诊断技术平台（于1992年推出），并支持13测试。他还发起和实施内部生产，此前外包给Abbott Diagnostics Inc.，以及WHO的这些产品的全球分销。他于1990年创立Immunometrics Ltd.（一个非营利WHO公司，世界各地销售和分销这些诊断产品）。
- Jacob Micallef,served as a Director of Belgian Volition between August 10, 2011 and March 31, 2016. Prior to the Share Exchange Agreement, he served as Chief Scientific Officer of Belgian Volition from October 11, 2010 to December 31, 2014, but was not otherwise involved with Singapore Volition. Dr. Micallef joined Cronos Therapeutics Limited, or Cronos, a company developing oncology drugs, in 2004, and in 2006, Cronos was listed in the United Kingdom on the Alternative Investment Market, or AIM, becoming ValiRx plc, or ValiRx (AIM:VAL). Dr. Micallef continued to work as Technical Officer for ValiRx, where he in-licensed the NucleosomicsTM technology and co-founded ValiBio SA, which is now Belgian Volition. From 2004 to 2007, he taught "science and enterprise" to science research workers from four universities at CASS Business School before joining Cronos. In 2001, Dr. Micallef co-founded Gene Expression Technologies, a company developing oncology drugs, where he successfully led the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer AG. Over a 15-year period, starting in 1985, Dr. Micallef worked for the World Health Organization, or WHO. While working for WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990, he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture, previously outsourced to Abbott Diagnostics Inc., and world-wide distribution of these products for WHO. Also, in 1990, he started a "not-for-profit" WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide. Dr. Micallef has over 20 years of experience in research and development and in the management of early-stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations. Dr. Micallef received his M.B.A. from Imperial College, University of London and his Ph.D. from King's College, University of London.
- Gael Forterre
Gael Forterre，我们的董事之一，自2021年1月起担任Volitionrx Limited的首席商务官，自2013年10月起担任Armori Capital Management LLC的管理合伙人。Forterre先生曾担任教育技术公司Path Education Inc.的董事，该公司于2021年5月与澳大利亚空白支票公司Path Group Inc.完成了业务合并。Forterre先生还于2018年1月至2018年12月担任PATH的首席财务官，并于2019年1月至2020年12月担任PATH的首席执行官。Forterre先生是Article22的联合创始人，这是一家专注于设计的社会企业，也曾于2013年7月至2021年6月担任其董事会成员。Forterre先生于2004年2月开始了他的职业生涯，担任Systeia Capital Management管理的事件驱动基金的对冲基金分析师，然后于2005年3月加入Alteram Asset Management。2005年9月，Forterre先生加入了法国巴黎银行纽约办事处的大宗商品衍生品团队。Forterre先生在巴黎第一大学获得金融硕士学位，并在哥伦比亚商学院和伦敦商学院获得双硕士学位。Forterre先生是我们董事之一Hadrien Forterre的兄弟。
Gael Forterre,one of our directors, has served as the Chief Commercial Officer of VolitionRx Limited since January 2021 and he has been a managing partner of Armori Capital Management LLC since October 2013. Mr. Forterre served as a director of Path Education Inc., an education technology company which consummated a business combination with Path Group Inc., an Australian blank-check company in May 2021. Mr. Forterre also served as Path's Chief Financial Officer from January 2018 to December 2018 and as Path's Chief Executive Officer from January 2019 to December 2020. Mr. Forterre is the co-founder of Article22 a design-focused social enterprise, and also served on its board of directors from July 2013 to June 2021. Mr. Forterre started his career in February 2004 as a hedge fund analyst for an event-driven fund managed by Systeia Capital Management and then joined Alteram Asset Management in March 2005. In September 2005 Mr. Forterre joined the commodity derivative team at BNP Paribas in their New York office. Mr. Forterre earned a Master's Degree in finance from Sorbonne Paris I and a double M.B.A from Columbia Business School and the London Business School. Mr. Forterre is the brother of Hadrien Forterre, one of our directors.- Gael Forterre，我们的董事之一，自2021年1月起担任Volitionrx Limited的首席商务官，自2013年10月起担任Armori Capital Management LLC的管理合伙人。Forterre先生曾担任教育技术公司Path Education Inc.的董事，该公司于2021年5月与澳大利亚空白支票公司Path Group Inc.完成了业务合并。Forterre先生还于2018年1月至2018年12月担任PATH的首席财务官，并于2019年1月至2020年12月担任PATH的首席执行官。Forterre先生是Article22的联合创始人，这是一家专注于设计的社会企业，也曾于2013年7月至2021年6月担任其董事会成员。Forterre先生于2004年2月开始了他的职业生涯，担任Systeia Capital Management管理的事件驱动基金的对冲基金分析师，然后于2005年3月加入Alteram Asset Management。2005年9月，Forterre先生加入了法国巴黎银行纽约办事处的大宗商品衍生品团队。Forterre先生在巴黎第一大学获得金融硕士学位，并在哥伦比亚商学院和伦敦商学院获得双硕士学位。Forterre先生是我们董事之一Hadrien Forterre的兄弟。
- Gael Forterre,one of our directors, has served as the Chief Commercial Officer of VolitionRx Limited since January 2021 and he has been a managing partner of Armori Capital Management LLC since October 2013. Mr. Forterre served as a director of Path Education Inc., an education technology company which consummated a business combination with Path Group Inc., an Australian blank-check company in May 2021. Mr. Forterre also served as Path's Chief Financial Officer from January 2018 to December 2018 and as Path's Chief Executive Officer from January 2019 to December 2020. Mr. Forterre is the co-founder of Article22 a design-focused social enterprise, and also served on its board of directors from July 2013 to June 2021. Mr. Forterre started his career in February 2004 as a hedge fund analyst for an event-driven fund managed by Systeia Capital Management and then joined Alteram Asset Management in March 2005. In September 2005 Mr. Forterre joined the commodity derivative team at BNP Paribas in their New York office. Mr. Forterre earned a Master's Degree in finance from Sorbonne Paris I and a double M.B.A from Columbia Business School and the London Business School. Mr. Forterre is the brother of Hadrien Forterre, one of our directors.
- Terig Hughes
Terig Hughes还自2022年12月1日起担任Volition America的首席财务官和财务主管，自2023年3月17日起担任Volition Vet的财务主管，自2021年9月2日起担任Volition Global Services的董事。在2021年9月1日至2022年8月8日期间，Hughes先生担任新加坡Volition的董事。Hughes先生从AUM Biosciences Pte. Ltd.加入公司，AUM Biosciences Pte. Ltd.是一家快速增长的生物技术公司，专注于开发用于癌症治疗的新药，他在新加坡担任首席财务官，负责监督业务和财务的各个方面，从2018年的初始创业到2020年首次获得收入。在2018年之前，Hughes先生曾在富时100指数公司RELX Group plc（前身为Reed Elsevier）的一个部门Elsevier担任多个高级财务和业务领导职务。从2014年到2017年，Hughes先生担任RELX Group plc印度和东南亚区域董事总经理，负责监督业务的各个方面，包括销售、市场营销和产品开发。2006年至2014年，他担任公司亚太区财务总监，期间管理和监督会计和财务职能，包括财务规划和分析。在此期间，他还监督了一个成功的财务转型项目，其中包括系统实施、向共享服务模式过渡、各种工作流的外包，以及在中国的多个并购项目。从2003年到2006年，休斯先生担任爱思唯尔美国期刊和医药传播部门的财务副总裁，在那里他为高级管理层提供商业支持，监督2002年《萨班斯-奥克斯利法案》要求的内部控制标准的实施，并管理年度定价过程。休斯先生通过跨越美国、欧洲和亚洲的国际职业生涯，拥有超过25年的会计、财务和商业管理经验。休斯先生在英国莱斯特的德蒙特福特大学获得会计和法律学士学位。
Terig Hughes,has also served as Chief Financial Officer and Treasurer of both Volition America since December 1, 2022, and of Volition Vet since March 17, 2023, as well as a Director of Volition Global Services since September 2, 2021. Between September 1, 2021 and August 8, 2022, Mr. Hughes served as a Director of Singapore Volition. Mr. Hughes joined the Company from AUM Biosciences Pte. Ltd., a fast-growing biotechnology company focused on developing novel drugs for cancer treatment, where he was the Chief Financial Officer based in Singapore, and oversaw all aspects of business and finance, from initial start-up in 2018 through to first revenue in 2020. Prior to 2018, Mr. Hughes held a number of senior finance and business leadership positions at Elsevier, a division of RELX Group plc (formerly Reed Elsevier), an FTSE 100 company. From 2014 to 2017, Mr. Hughes was the regional Managing Director of RELX Group plc for India and Southeast Asia, overseeing all aspects of the business including sales, marketing, and product development. From 2006 to 2014, he served as the company's Finance Director for Asia Pacific, during which he managed and oversaw accounting and finance functions, including financial planning and analysis. During this period, he also oversaw a successful finance transformation project, which included systems implementation, transition to a shared-services model, and outsourcing of various work streams, as well as a number of mergers and acquisitions projects in China. From 2003 to 2006, Mr. Hughes was the Vice President Finance of Elsevier's US Journals and Pharma Communications Division where he provided commercial support to senior management, oversaw implementation of internal control standards as required by the Sarbanes-Oxley Act of 2002, and managed the annual pricing process. Mr. Hughes has over 25 years of accounting, finance and business management experience gained through an international career spanning the United States, Europe and Asia. Mr. Hughes received a B.Sc. in Accounting and Law from De Montfort University, Leicester in the United Kingdom.- Terig Hughes还自2022年12月1日起担任Volition America的首席财务官和财务主管，自2023年3月17日起担任Volition Vet的财务主管，自2021年9月2日起担任Volition Global Services的董事。在2021年9月1日至2022年8月8日期间，Hughes先生担任新加坡Volition的董事。Hughes先生从AUM Biosciences Pte. Ltd.加入公司，AUM Biosciences Pte. Ltd.是一家快速增长的生物技术公司，专注于开发用于癌症治疗的新药，他在新加坡担任首席财务官，负责监督业务和财务的各个方面，从2018年的初始创业到2020年首次获得收入。在2018年之前，Hughes先生曾在富时100指数公司RELX Group plc（前身为Reed Elsevier）的一个部门Elsevier担任多个高级财务和业务领导职务。从2014年到2017年，Hughes先生担任RELX Group plc印度和东南亚区域董事总经理，负责监督业务的各个方面，包括销售、市场营销和产品开发。2006年至2014年，他担任公司亚太区财务总监，期间管理和监督会计和财务职能，包括财务规划和分析。在此期间，他还监督了一个成功的财务转型项目，其中包括系统实施、向共享服务模式过渡、各种工作流的外包，以及在中国的多个并购项目。从2003年到2006年，休斯先生担任爱思唯尔美国期刊和医药传播部门的财务副总裁，在那里他为高级管理层提供商业支持，监督2002年《萨班斯-奥克斯利法案》要求的内部控制标准的实施，并管理年度定价过程。休斯先生通过跨越美国、欧洲和亚洲的国际职业生涯，拥有超过25年的会计、财务和商业管理经验。休斯先生在英国莱斯特的德蒙特福特大学获得会计和法律学士学位。
- Terig Hughes,has also served as Chief Financial Officer and Treasurer of both Volition America since December 1, 2022, and of Volition Vet since March 17, 2023, as well as a Director of Volition Global Services since September 2, 2021. Between September 1, 2021 and August 8, 2022, Mr. Hughes served as a Director of Singapore Volition. Mr. Hughes joined the Company from AUM Biosciences Pte. Ltd., a fast-growing biotechnology company focused on developing novel drugs for cancer treatment, where he was the Chief Financial Officer based in Singapore, and oversaw all aspects of business and finance, from initial start-up in 2018 through to first revenue in 2020. Prior to 2018, Mr. Hughes held a number of senior finance and business leadership positions at Elsevier, a division of RELX Group plc (formerly Reed Elsevier), an FTSE 100 company. From 2014 to 2017, Mr. Hughes was the regional Managing Director of RELX Group plc for India and Southeast Asia, overseeing all aspects of the business including sales, marketing, and product development. From 2006 to 2014, he served as the company's Finance Director for Asia Pacific, during which he managed and oversaw accounting and finance functions, including financial planning and analysis. During this period, he also oversaw a successful finance transformation project, which included systems implementation, transition to a shared-services model, and outsourcing of various work streams, as well as a number of mergers and acquisitions projects in China. From 2003 to 2006, Mr. Hughes was the Vice President Finance of Elsevier's US Journals and Pharma Communications Division where he provided commercial support to senior management, oversaw implementation of internal control standards as required by the Sarbanes-Oxley Act of 2002, and managed the annual pricing process. Mr. Hughes has over 25 years of accounting, finance and business management experience gained through an international career spanning the United States, Europe and Asia. Mr. Hughes received a B.Sc. in Accounting and Law from De Montfort University, Leicester in the United Kingdom.
- Gaetan Michel
Gaetan Michel，自2021年11月16日起担任Volition America的董事和首席执行官，分别自2021年9月15日和2021年9月1日起担任Volition Global Services的首席执行官和经理，分别自2019年8月7日和2021年5月1日起担任Volition Veterinary的经理和总裁，自2022年11月15日起担任比利时Volition的首席执行官和经理。此外，自2015年6月22日至2021年11月4日，米歇尔博士担任比利时Volition的经理，自2015年7月1日至2021年9月14日担任比利时Volition的首席执行官，自2020年8月14日至2021年5月1日担任Volition Veterinary的首席执行官，自2020年1月10日至2020年10月23日担任Volition Germany GmbH的董事总经理。Michel博士此前还曾在2014年7月至2018年6月期间担任比利时Volition的首席运营官。Michel博士在生产管理方面拥有超过十年的经验。在加入比利时Volition之前，2010年至2014年，Michel博士在Bone Therapeutics SA（Euronext Brussels and Paris：BOTHE）担任生产总监，这是一家以骨细胞治疗为基础的制药公司，他的职责包括建立两个新的生产工厂，开始为两个III期临床试验进行生产，为与比利时卫生当局谈判的新产品开发质量体系，以及为一种可注射医疗设备建立产品工厂。2007年至2010年，米歇尔博士任职于KitoZyme，这是一家全球性的真菌来源生物聚合物制造商，其核心业务是体重管理、消化和心血管健康。在此期间，Dr. Michel建立了生产和工艺开发部门，并监督公司工业阶段的开始，最终推出了首批产品。在加入KitoZyme之前，继2002年完成博士学位后，Michel博士加入了Advanced Array Technologies，即AAT，这是一家那慕尔大学的衍生公司，担任蛋白质组学项目经理。AAT后来成为Eppendorf Array Technologies，隶属于德国Eppendorf生物技术公司，Michel博士在那里成为生产经理，并参与建立生产工艺和设备。Michel博士获得比利时那慕尔大学生物化学博士学位。
Gaetan Michel,has served as Director and Chief Executive Officer of Volition America since November 16, 2021, as Chief Executive Officer and Manager of Volition Global Services since September 15, 2021 and September 1, 2021, respectively, as Manager and President of Volition Veterinary since August 7, 2019 and May 1, 2021, respectively, and as Chief Executive Officer and Manager of Belgian Volition since November 15, 2022. In addition, from June 22, 2015 to November 4, 2021, Dr. Michel served as Manager of Belgian Volition, from July 1, 2015 to September 14, 2021 as Chief Executive Officer of Belgian Volition, from August 14, 2020 to May 1, 2021 as Chief Executive Officer of Volition Veterinary, and from January 10, 2020 to October 23, 2020, as a Managing Director of Volition Germany GmbH. Dr. Michel also previously served as Belgian Volition's Chief Operations Officer from July 2014 to June 2018. Dr. Michel has over ten years of experience in production management. Prior to joining Belgian Volition, from 2010 to 2014 Dr. Michel worked as production director for Bone Therapeutics SA (Euronext Brussels and Paris: BOTHE), a bone cell therapy-based pharmaceutical company, where his responsibilities included establishing two new production plants to commence manufacturing for two phase III clinical trials, developing quality systems for new products in negotiation with the Belgian health authorities, and establishing a product plant for an injectable medical device. From 2007 to 2010, Dr. Michel worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health. During this period, Dr. Michel established both the production and process development departments and oversaw the commencement of the company's industrial phase culminating in the roll out of first products. Prior to joining KitoZyme, following the completion of his Ph.D. in 2002, Dr. Michel joined Advanced Array Technologies, or AAT, a University of Namur spin-off company as project manager in proteomics. AAT later became Eppendorf Array Technologies, part of the German Eppendorf biotech company, where Dr. Michel became production manager and was involved in establishing production processes and equipment. Dr. Michel received a Ph.D. in Biochemistry from the University of Namur, Belgium.- Gaetan Michel，自2021年11月16日起担任Volition America的董事和首席执行官，分别自2021年9月15日和2021年9月1日起担任Volition Global Services的首席执行官和经理，分别自2019年8月7日和2021年5月1日起担任Volition Veterinary的经理和总裁，自2022年11月15日起担任比利时Volition的首席执行官和经理。此外，自2015年6月22日至2021年11月4日，米歇尔博士担任比利时Volition的经理，自2015年7月1日至2021年9月14日担任比利时Volition的首席执行官，自2020年8月14日至2021年5月1日担任Volition Veterinary的首席执行官，自2020年1月10日至2020年10月23日担任Volition Germany GmbH的董事总经理。Michel博士此前还曾在2014年7月至2018年6月期间担任比利时Volition的首席运营官。Michel博士在生产管理方面拥有超过十年的经验。在加入比利时Volition之前，2010年至2014年，Michel博士在Bone Therapeutics SA（Euronext Brussels and Paris：BOTHE）担任生产总监，这是一家以骨细胞治疗为基础的制药公司，他的职责包括建立两个新的生产工厂，开始为两个III期临床试验进行生产，为与比利时卫生当局谈判的新产品开发质量体系，以及为一种可注射医疗设备建立产品工厂。2007年至2010年，米歇尔博士任职于KitoZyme，这是一家全球性的真菌来源生物聚合物制造商，其核心业务是体重管理、消化和心血管健康。在此期间，Dr. Michel建立了生产和工艺开发部门，并监督公司工业阶段的开始，最终推出了首批产品。在加入KitoZyme之前，继2002年完成博士学位后，Michel博士加入了Advanced Array Technologies，即AAT，这是一家那慕尔大学的衍生公司，担任蛋白质组学项目经理。AAT后来成为Eppendorf Array Technologies，隶属于德国Eppendorf生物技术公司，Michel博士在那里成为生产经理，并参与建立生产工艺和设备。Michel博士获得比利时那慕尔大学生物化学博士学位。
- Gaetan Michel,has served as Director and Chief Executive Officer of Volition America since November 16, 2021, as Chief Executive Officer and Manager of Volition Global Services since September 15, 2021 and September 1, 2021, respectively, as Manager and President of Volition Veterinary since August 7, 2019 and May 1, 2021, respectively, and as Chief Executive Officer and Manager of Belgian Volition since November 15, 2022. In addition, from June 22, 2015 to November 4, 2021, Dr. Michel served as Manager of Belgian Volition, from July 1, 2015 to September 14, 2021 as Chief Executive Officer of Belgian Volition, from August 14, 2020 to May 1, 2021 as Chief Executive Officer of Volition Veterinary, and from January 10, 2020 to October 23, 2020, as a Managing Director of Volition Germany GmbH. Dr. Michel also previously served as Belgian Volition's Chief Operations Officer from July 2014 to June 2018. Dr. Michel has over ten years of experience in production management. Prior to joining Belgian Volition, from 2010 to 2014 Dr. Michel worked as production director for Bone Therapeutics SA (Euronext Brussels and Paris: BOTHE), a bone cell therapy-based pharmaceutical company, where his responsibilities included establishing two new production plants to commence manufacturing for two phase III clinical trials, developing quality systems for new products in negotiation with the Belgian health authorities, and establishing a product plant for an injectable medical device. From 2007 to 2010, Dr. Michel worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health. During this period, Dr. Michel established both the production and process development departments and oversaw the commencement of the company's industrial phase culminating in the roll out of first products. Prior to joining KitoZyme, following the completion of his Ph.D. in 2002, Dr. Michel joined Advanced Array Technologies, or AAT, a University of Namur spin-off company as project manager in proteomics. AAT later became Eppendorf Array Technologies, part of the German Eppendorf biotech company, where Dr. Michel became production manager and was involved in establishing production processes and equipment. Dr. Michel received a Ph.D. in Biochemistry from the University of Namur, Belgium.
- Andrew Retter
Andrew Retter，是一位英国医生，拥有超过20年的经验。Retter博士自2014年以来一直在综合医学委员会血液学和重症监护医学专家名册上，并于2014年加入伦敦盖伊和圣托马斯NHS基金会信托基金的团队。Retter博士参与了临床试验和研究，在同行评审的医学期刊上发表了50多篇文章。他的专长领域包括血液系统恶性肿瘤的管理以及复杂凝血障碍、抗凝和败血症的管理。除了临床工作外，雷特博士还是一位卓有成就的教育家和导师。他教授和培训医学生、住院医师和研究员，并担任教育课程的教员。Retter博士于2001年从圣乔治医院医学院获得医学学位，并于2013年在伦敦圣托马斯医院完成了血液学和重症监护医学的研究生培训。
Andrew Retter,is a United Kingdom-based doctor with over 20 years of experience. Dr. Retter has been on the Specialist Register of the General Medical Council in Hematology and Intensive Care Medicine since 2014 and joined the team at Guy's and St. Thomas' NHS Foundation Trust in London in 2014. Dr. Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. His areas of expertise include the management of hematological malignancies and the management of complex coagulopathies, anticoagulation, and sepsis. In addition to his clinical work, Dr. Retter is also an accomplished educator and mentor. He teaches and trains medical students, residents, and fellows, and has served as a faculty member for educational courses. Dr. Retter obtained his medical degree from St. George's Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas' Hospital in London in 2013.- Andrew Retter，是一位英国医生，拥有超过20年的经验。Retter博士自2014年以来一直在综合医学委员会血液学和重症监护医学专家名册上，并于2014年加入伦敦盖伊和圣托马斯NHS基金会信托基金的团队。Retter博士参与了临床试验和研究，在同行评审的医学期刊上发表了50多篇文章。他的专长领域包括血液系统恶性肿瘤的管理以及复杂凝血障碍、抗凝和败血症的管理。除了临床工作外，雷特博士还是一位卓有成就的教育家和导师。他教授和培训医学生、住院医师和研究员，并担任教育课程的教员。Retter博士于2001年从圣乔治医院医学院获得医学学位，并于2013年在伦敦圣托马斯医院完成了血液学和重症监护医学的研究生培训。
- Andrew Retter,is a United Kingdom-based doctor with over 20 years of experience. Dr. Retter has been on the Specialist Register of the General Medical Council in Hematology and Intensive Care Medicine since 2014 and joined the team at Guy's and St. Thomas' NHS Foundation Trust in London in 2014. Dr. Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. His areas of expertise include the management of hematological malignancies and the management of complex coagulopathies, anticoagulation, and sepsis. In addition to his clinical work, Dr. Retter is also an accomplished educator and mentor. He teaches and trains medical students, residents, and fellows, and has served as a faculty member for educational courses. Dr. Retter obtained his medical degree from St. George's Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas' Hospital in London in 2013.
- Nicholas Plummer
Nicholas Plummer，是一名在英格兰获得律师资格的律师。1995年至2004年，Plummer先生曾在英国和国际律师事务所Ashurst担任公司律师，之后于2004年至2008年首次担任英国上市生物技术公司Ark Therapeutics Group PLC的总法律顾问和公司秘书。2013年至2021年，Plummer先生担任Patheon的欧盟管理顾问，随后担任合同药物开发商和制造商赛默飞世尔的制药服务集团。Plummer先生在私人执业和内部角色方面拥有三十年的法律经验，主要在医疗保健领域。Plummer先生拥有雷丁大学法学学士学位（荣誉），并于1997年被英格兰和威尔士最高法院录取为律师。
Nicholas Plummer,is a solicitor qualified in England. From 1995 to 2004, Mr. Plummer worked at the United Kingdom and international law firm Ashurst as a corporate lawyer, before moving into his first in-house role as General Counsel and Company Secretary of Ark Therapeutics Group PLC, a UK-listed biotech company, from 2004 to 2008. From 2013 to 2021, Mr. Plummer served as the EU Managing Counsel at Patheon, subsequently Pharma Services Group of Thermo Fisher Scientific, a contract drug developer and manufacturer. Mr. Plummer has thirty years of legal experience in private practice and in-house roles, primarily in the healthcare sector. Mr. Plummer holds a LL.B. law degree (Hons) from Reading University and was admitted as a Solicitor to the Supreme Court of England and Wales in 1997.- Nicholas Plummer，是一名在英格兰获得律师资格的律师。1995年至2004年，Plummer先生曾在英国和国际律师事务所Ashurst担任公司律师，之后于2004年至2008年首次担任英国上市生物技术公司Ark Therapeutics Group PLC的总法律顾问和公司秘书。2013年至2021年，Plummer先生担任Patheon的欧盟管理顾问，随后担任合同药物开发商和制造商赛默飞世尔的制药服务集团。Plummer先生在私人执业和内部角色方面拥有三十年的法律经验，主要在医疗保健领域。Plummer先生拥有雷丁大学法学学士学位（荣誉），并于1997年被英格兰和威尔士最高法院录取为律师。
- Nicholas Plummer,is a solicitor qualified in England. From 1995 to 2004, Mr. Plummer worked at the United Kingdom and international law firm Ashurst as a corporate lawyer, before moving into his first in-house role as General Counsel and Company Secretary of Ark Therapeutics Group PLC, a UK-listed biotech company, from 2004 to 2008. From 2013 to 2021, Mr. Plummer served as the EU Managing Counsel at Patheon, subsequently Pharma Services Group of Thermo Fisher Scientific, a contract drug developer and manufacturer. Mr. Plummer has thirty years of legal experience in private practice and in-house roles, primarily in the healthcare sector. Mr. Plummer holds a LL.B. law degree (Hons) from Reading University and was admitted as a Solicitor to the Supreme Court of England and Wales in 1997.
- Louise Batchelor
Louise Batchelor，于2016年4月从ACULD Limited加入公司，ACULD Limited是一家专注于医疗保健的战略营销咨询公司，自2011年8月起担任董事和所有者。从2006年4月到2009年1月，Batchelor女士担任英国跨国消费品公司Reckitt Benckiser Plc的全球品牌营销经理，在那里她领导了Lysol全球品牌的开发细菌保护范围。从2001年到2009年，Batchelor女士还担任Reckitt Benckiser的欧洲业务部门主管，总部设在法国巴黎，负责欧洲业务的一般管理，并领导了欧洲监管战略和多个产品的推出。在加入Reckitt Benckiser之前，Batchelor女士曾于1993年8月至2000年10月在英国Zeneca Pharmaceuticals Ltd担任产品经理、营销主管、初级保健领域销售经理和高级市场研究主管。Batchelor女士通过跨越美国、欧洲和英国的国际职业生涯，拥有三十年的全球营销、销售和领导经验。Batchelor女士获得了谢菲尔德哈勒姆大学商学学士学位。
Louise Batchelor,joined the Company in April 2016 from ACULD Limited, a strategic marketing consultancy specializing in healthcare where she served as director and owner since August 2011. From April 2006 to January 2009, Ms. Batchelor was the global brand marketing manager for Reckitt Benckiser Plc, a British, multinational consumer goods company, where she led the development of the global brand for the Lysol germ protection range. From 2001 to 2009, Ms. Batchelor also served as the European business unit director for Reckitt Benckiser, based in Paris, France, where she was responsible for general management of the European business and led the European regulatory strategy and launch of multiple products. Prior to joining Reckitt Benckiser, Ms. Batchelor was a product manager, marketing executive, primary care field sales manager and a senior market research executive at Zeneca Pharmaceuticals Ltd in the United Kingdom, from August 1993 to October 2000. Ms. Batchelor has thirty years of global marketing, sales and leadership experience gained through an international career spanning the United States, Europe and the United Kingdom. Ms. Batchelor received a B.A. in business studies from Sheffield Hallam University.- Louise Batchelor，于2016年4月从ACULD Limited加入公司，ACULD Limited是一家专注于医疗保健的战略营销咨询公司，自2011年8月起担任董事和所有者。从2006年4月到2009年1月，Batchelor女士担任英国跨国消费品公司Reckitt Benckiser Plc的全球品牌营销经理，在那里她领导了Lysol全球品牌的开发细菌保护范围。从2001年到2009年，Batchelor女士还担任Reckitt Benckiser的欧洲业务部门主管，总部设在法国巴黎，负责欧洲业务的一般管理，并领导了欧洲监管战略和多个产品的推出。在加入Reckitt Benckiser之前，Batchelor女士曾于1993年8月至2000年10月在英国Zeneca Pharmaceuticals Ltd担任产品经理、营销主管、初级保健领域销售经理和高级市场研究主管。Batchelor女士通过跨越美国、欧洲和英国的国际职业生涯，拥有三十年的全球营销、销售和领导经验。Batchelor女士获得了谢菲尔德哈勒姆大学商学学士学位。
- Louise Batchelor,joined the Company in April 2016 from ACULD Limited, a strategic marketing consultancy specializing in healthcare where she served as director and owner since August 2011. From April 2006 to January 2009, Ms. Batchelor was the global brand marketing manager for Reckitt Benckiser Plc, a British, multinational consumer goods company, where she led the development of the global brand for the Lysol germ protection range. From 2001 to 2009, Ms. Batchelor also served as the European business unit director for Reckitt Benckiser, based in Paris, France, where she was responsible for general management of the European business and led the European regulatory strategy and launch of multiple products. Prior to joining Reckitt Benckiser, Ms. Batchelor was a product manager, marketing executive, primary care field sales manager and a senior market research executive at Zeneca Pharmaceuticals Ltd in the United Kingdom, from August 1993 to October 2000. Ms. Batchelor has thirty years of global marketing, sales and leadership experience gained through an international career spanning the United States, Europe and the United Kingdom. Ms. Batchelor received a B.A. in business studies from Sheffield Hallam University.
- Jasmine Kway
Jasmine Kway，担任新加坡Volition首席执行官。Kway博士此前曾于2017年1月至2018年6月担任新加坡Volition亚洲区副总裁。在加入新加坡Volition之前，Kway博士在2016年期间担任RHT i-Assets Advisory（RHTiAA）知识产权业务首席执行官，该公司是一家总部位于新加坡的专业服务公司，在亚洲提供投资和技术商业化服务。在RHTiAA期间，Kway博士专注于在技术和知识产权交易、业务发展和资金筹集方面管理全球买方和卖方客户。在加入RHTIAA之前，Kway博士曾在私营和公共部门工作，包括2010年至2015年在提供全方位服务的知识产权公司Transpacific IP Group Limited担任执行副总裁，并于2005年至2010年担任新加坡国立大学行业联络主任。在这些岗位上，KWAY博士制定并实施了国家知识产权政策、企业知识产权战略与管理、知识产权与技术开发、商业化、筹资、投资等工作。Kway博士在新加坡国立大学获得工学学士（荣誉）和博士学位。
Jasmine Kway,serves as the Chief Executive Officer of Singapore Volition. Dr. Kway previously served as Singapore Volition's Vice President of Asia from January 2017 until June 2018. Prior to joining Singapore Volition, during 2016 Dr. Kway served as Chief Executive Officer of intellectual property practice at RHT i-Assets Advisory, or RHTiAA, a Singapore-headquartered professional services company providing investments and technology commercialization services in Asia. While at RHTiAA, Dr. Kway was focused on managing buy-side and sell-side clients globally in technology and intellectual property transactions, business development, and fund raising. Prior to RHTiAA, Dr. Kway worked in both the private and public sectors, including as Executive Vice President at Transpacific IP Group Limited, a full-service intellectual property company, from 2010 to 2015, and as Director of Industry Liaison of the National University of Singapore from 2005 to 2010. In these positions, Dr. Kway formulated and implemented national intellectual property policies, corporate intellectual property strategies and management, intellectual property and technology development, commercialization, fundraising, and investment. Dr. Kway received her Bachelor of Engineering (Honors) and Doctorate degrees from the National University of Singapore.- Jasmine Kway，担任新加坡Volition首席执行官。Kway博士此前曾于2017年1月至2018年6月担任新加坡Volition亚洲区副总裁。在加入新加坡Volition之前，Kway博士在2016年期间担任RHT i-Assets Advisory（RHTiAA）知识产权业务首席执行官，该公司是一家总部位于新加坡的专业服务公司，在亚洲提供投资和技术商业化服务。在RHTiAA期间，Kway博士专注于在技术和知识产权交易、业务发展和资金筹集方面管理全球买方和卖方客户。在加入RHTIAA之前，Kway博士曾在私营和公共部门工作，包括2010年至2015年在提供全方位服务的知识产权公司Transpacific IP Group Limited担任执行副总裁，并于2005年至2010年担任新加坡国立大学行业联络主任。在这些岗位上，KWAY博士制定并实施了国家知识产权政策、企业知识产权战略与管理、知识产权与技术开发、商业化、筹资、投资等工作。Kway博士在新加坡国立大学获得工学学士（荣誉）和博士学位。
- Jasmine Kway,serves as the Chief Executive Officer of Singapore Volition. Dr. Kway previously served as Singapore Volition's Vice President of Asia from January 2017 until June 2018. Prior to joining Singapore Volition, during 2016 Dr. Kway served as Chief Executive Officer of intellectual property practice at RHT i-Assets Advisory, or RHTiAA, a Singapore-headquartered professional services company providing investments and technology commercialization services in Asia. While at RHTiAA, Dr. Kway was focused on managing buy-side and sell-side clients globally in technology and intellectual property transactions, business development, and fund raising. Prior to RHTiAA, Dr. Kway worked in both the private and public sectors, including as Executive Vice President at Transpacific IP Group Limited, a full-service intellectual property company, from 2010 to 2015, and as Director of Industry Liaison of the National University of Singapore from 2005 to 2010. In these positions, Dr. Kway formulated and implemented national intellectual property policies, corporate intellectual property strategies and management, intellectual property and technology development, commercialization, fundraising, and investment. Dr. Kway received her Bachelor of Engineering (Honors) and Doctorate degrees from the National University of Singapore.